Ensysce Biosciences Inc
ENSC
查看详细走势图
1.425USD
+0.005+0.35%
收盘 12/12, 16:00（美东）报价延迟15分钟
4.53M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.35%
5天
-13.11%
1月
-31.16%
6月
-31.16%
今年开始到现在
-82.49%
1年
-74.64%
查看详细走势图
TradingKey Ensysce Biosciences Inc股票评分
单位: USD 更新时间: 2025-12-12操作建议
Ensysce Biosciences Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名235/404位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价26.23。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Ensysce Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
26.225
目标均价
+1539.06%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Ensysce Biosciences Inc亮点
亮点风险
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
业绩高增长
公司营业收入稳步增长，连续3年增长106.47%
业绩增长期
公司处于发展阶段，最新年度总收入5.21M美元
估值高估
公司最新PE估值-0.22，处于3年历史高位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值36.71K
Ensysce Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Ensysce Biosciences Inc简介
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
公司代码ENSC
公司Ensysce Biosciences Inc
CEOKirkpatrick (Lynn D)
网址https://ensysce.com/
常见问题
Ensysce Biosciences Inc(ENSC)的当前股价是多少？
Ensysce Biosciences Inc(ENSC)的当前股价是 1.425。
Ensysce Biosciences Inc的股票代码是什么？
Ensysce Biosciences Inc的股票代码是ENSC。
Ensysce Biosciences Inc股票的52周最高点是多少？
Ensysce Biosciences Inc股票的52周最高点是10.960。
Ensysce Biosciences Inc股票的52周最低点是多少？
Ensysce Biosciences Inc股票的52周最低点是1.260。
Ensysce Biosciences Inc的市值是多少？
Ensysce Biosciences Inc的市值是4.53M。
Ensysce Biosciences Inc的净利润是多少？
Ensysce Biosciences Inc的净利润为-7.99M。
现在Ensysce Biosciences Inc(ENSC)的股票是买入、持有还是卖出？
根据分析师评级，Ensysce Biosciences Inc(ENSC)的总体评级为--，目标价格为26.225。
Ensysce Biosciences Inc(ENSC)股票的每股收益（EPS TTM）是多少
Ensysce Biosciences Inc(ENSC)股票的每股收益（EPS TTM）是-6.340。
相关品种
